A Clinical trial of LNR 125.38
Latest Information Update: 08 Oct 2021
At a glance
- Drugs LNR 125.38 (Primary)
- Indications Asthma; Atopic dermatitis; Chronic urticaria; Eosinophilic oesophagitis; Food hypersensitivity; Gastroenteritis; Rhinosinusitis
- Focus Adverse reactions
- Sponsors Lanier Biotherapeutics
- 08 Oct 2021 New trial record
- 05 Oct 2021 According to a Lanier Biotherapeutics media release, the company plans to initiate investigational new drug (IND) enabling studies of LNR 125.38 in 2022.